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The need to stem the growing problem of antimicrobial resistance has prompted multiple, sometimes con-
flicting, calls for changes in the use of antimicrobial agents. One source of disagreement concerns the
major mechanisms by which antibiotics select resistant strains. For infections like tuberculosis, in which
resistance can emerge in treated hosts through mutation, prevention of antimicrobial resistance in individ-
ual hosts is a primary method of preventing the spread of resistant organisms in the community. By con-
trast, for many other important resistant pathogens, such as penicillin-resistant Streptococcus
pneumoniae, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus
faecium resistance is mediated by the acquisition of genes or gene fragments by horizontal transfer; resis-
tance in the treated host is a relatively rare event. For these organisms, indirect, population-level mecha-
nisms of selection account for the increase in the prevalence of resistance. These mechanisms can
operate even when treatment has a modest, or even negative, effect on an individual host’s colonization
with resistant organisms. 
he growth of antimicrobial resistance has prompted calls
to reduce unnecessary antibiotic use and to improve treat-
ment protocols to maximize the lifespan of these drugs.  These
calls rest on the well-supported idea that the use of antimicro-
bial agents is a powerful selective force that promotes the
emergence of resistant strains. 
To reduce antimicrobial resistance, multiple, and often
conflicting recommendations, have been made. For example,
strategies to minimize the burden of resistance in hospitals
have included reduction of all antimicrobial classes, increased
use of prophylactic antimicrobials to reduce colonization, rota-
tion of different antibiotic classes in a temporal sequence, and
simultaneous use of different antimicrobials  for different
patients (1-6). 
Underlying these often varying recommendations for
improving antimicrobial use is frequently conflicting evidence
about the relationship between antibiotic treatment and antibi-
otic resistance. In some pathogens, showing that antibiotic treat-
ment puts treated persons at a greater risk for acquiring resistant
organisms has been difficult (7-8); nonetheless, the cumulative
effect of using these antibiotics has clearly been to increase the
prevalence of resistance in the population as a whole.
For many pathogens of current concern, especially organ-
isms for which asymptomatic colonization typically precedes
infection (e.g., Streptococcus pneumoniae,  Staphylococcus
aureus, Enterococcus spp., and the gram-negative enteric bac-
teria), the relationship between antimicrobial use and resis-
tance differs in fundamental ways from the relationship found
in Mycobacterium tuberculosis, for which many modern prin-
ciples of chemotherapy were developed. Furthermore, we
argue that the selective effects of antibiotic use on these organ-
isms are poorly understood, and we make specific suggestions
for studies that could improve understanding of the mecha-
nisms by which antibiotics exert natural selection on these
organisms. Such an understanding will be crucial for the
design of rational policies of antibiotic use to maximize the
lifespan of existing drugs and to minimize the impact of resis-
tant infections. 
Resistance in People and Populations
Ehrlich’s advice that treatment of infections should “hit
hard and hit early,” formulated in the earliest days of antimi-
crobial chemotherapy, presciently summarized the principles
of treatment for infections such as tuberculosis (TB) (9). These
principles are embodied in modern protocols of directly
observed, short-course chemotherapy, where the goal is to
treat with adequate concentrations of multiple drugs and main-
tain treatment until the bacterial population is extinct. Resis-
tance to each of the major antituberculosis drugs is mediated
by single point mutation; therefore tuberculosis treatment is
designed to prevent the ascent of subpopulations of mutant
bacilli that are resistant to any one of the drugs. Similar princi-
ples have been suggested for other infections in which resis-
tance can arise by simple mutation, most notably HIV (9),
although there has been some controversy on this topic (11). In
these infections, the relationship between treatment, resistance
in the treated person, and resistance in the community at large
is relatively clear. Inadequate therapy (owing to subtherapeutic
drug concentrations, too few drugs, or poor adherence to ther-
apy) results in the emergence of resistance, and possibly treat-
ment failure, in the treated host. Following the emergence of
resistance in the treated host, resistant infections may be trans-
mitted to others. (Figure, A; Table).
For many pathogens, both the genetics and the epidemiol-
ogy of resistance differ from those of TB in important ways.
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For example, methicillin resistance in S. aureus and vancomy-
cin resistance in Enterococcus are mediated by the acquisition
of one or several new genes, rather than by point mutations in
existing genes. In Streptococcus pneumoniae, penicillin resis-
tance occurs when segments of wild-type penicillin-binding
protein genes are replaced with alleles whose sequences differ
from the wild-type at multiple positions. These new resistance
mechanisms arose and spread in large populations under con-
ditions of antibiotic selection pressure, but they are unlikely to
occur de novo in any single person because of the multiple
changes involved. Organisms (or plasmids) bearing these
types of resistance must be acquired, generally as a conse-
quence of cross-transmission. Furthermore, most of these
organisms are not obligate pathogens such as HIV or TB; as a
result, much of their exposure to antibiotics occurs during
treatment directed at infections caused by other, unrelated
organisms. 
Because of these genetic and epidemiologic differences,
the paradigm for tuberculosis treatment, minimizing resistance
in the treated host and the community by preventing the emer-
gence of resistant subpopulations during treatment, is often
inapplicable to these organisms (12). Antibiotic treatment pro-
motes the spread of these organisms, as suggested by the rapid
increases in resistance in many of the organisms after the new
drug classes are introduced. However, the effects of treatment
in promoting resistance occur by less direct mechanisms,
which depend on competitive interactions between drug-resis-
tant and drug-susceptible strains.
Figure. Four mechanisms by which antibiotic treatment can create selection for resistance in the population, showing direct effects—increased
resistance in treated (yellow) vs. untreated (white) hosts, and indirect effects—increased resistance in others (turquoise) due to treatment of spe-
cific hosts. (A) Subpopulations (usually mutants) of resistant (red) bacteria are present in a host infected with a predominantly susceptible (green)
strain; treatment fails, resulting in outgrowth of the resistant subpopulation, which can then be transmitted to other, susceptible hosts (turquoise).
(B) Successful treatment of an individual infected with a susceptible strain reduces the ability of that host to transmit the infection to other suscep-
tible hosts, making those hosts more likely to be infected by resistant pathogens than they would otherwise have been, and shifting the competitive
balance toward resistant infections. (C) Treatment of an infection eradicates a population of susceptible bacteria carried (often commensally) by
the host, making that host more susceptible to acquisition of a new strain. If the newly acquired strain has a high probability of being resistant (as
in the context of an outbreak of a resistant strain), this can significantly increase the treated individual’s risk of carrying a resistant strain, relative to
an untreated one. (D) Treatment of an infection in an individual who is already colonized (commensally) with resistant organisms may result in
increased load of those organisms if competing flora (perhaps of another species) are inhibited—leading to increased shedding of the resistant
organism and possibly to increased individual risk of infection with the resistant organism.
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Indirect Effects on Resistance
For any infectious disease, the infection or colonization
status of any one (index) patient affects the risk of infection or
colonization of others. Measures (such as vaccination or anti-
biotic treatment) that change the incidence or duration of
infection in one person will affect that person’s contacts (13-
14). Just as vaccination programs benefit those who are not
vaccinated because of the phenomenon of herd immunity, anti-
biotic usage by some persons may increase the risk of coloni-
zation or infection with resistant organisms in people who
have not received antibiotics. Members of a population experi-
ence indirect effects of antimicrobial use, defined as the
enhancement of risk for acquiring a resistant organism,
because of the use of antimicrobials by other persons in the
group or population.
For example, simply by eradicating susceptible organisms,
and thereby reducing the opportunities for transmission of sus-
ceptible strains, antibiotics received by treated hosts can
increase the probability that other hosts will acquire resistant
variants (Figure, B; Table). For many pathogens, acquisition of
one strain reduces a person's chances of acquiring other
strains, either via immune responses, via direct interference
(15-17), or both. These inhibitory interactions create competi-
tion between resistant and susceptible strains. As a result,
treatment of some patients, by eradicating susceptible strains
and thereby reducing their ability to transmit to other hosts, is
advantageous to resistant strains in the population. Mathemati-
cal models (18-22) and epidemiologic studies (23) suggest that
this mechanism of shifting the competitive balance in favor of
resistant strains can increase the prevalence of resistant organ-
isms in the community, alone or in combination with other
mechanisms. An important feature of this kind of indirect
effect is that it need not involve an increase in a patient’s own
risk of carrying resistant organisms, only a reduction in the
duration or probability of carrying susceptible ones.
In these organisms, the increase in transmission of resistant
pathogens is a consequence of successful treatment of the
infected host, resulting in the eradication of drug-susceptible
pathogens that colonize or infect that host. As a consequence,
the more effective a treatment is at eradicating drug-suscepti-
ble populations of these organisms, the more it will promote
the spread of resistant ones. This spread contrasts with TB, in
which treatment failure is often associated with the emergence
of resistance in treated hosts, so unsuccessful treatment is seen
as a factor promoting the spread of resistance (although, over a
time scale of decades, this type of indirect mechanism
described here may play a role even in tuberculosis [21]).
Combinations of Direct and 
Indirect Effects on Resistance
A third mechanism by which antimicrobial use increases
the number of patients colonized or infected with resistant
organisms is by modifying the treated host’s colonization
resistance (Figure, C; Table). Eradication or reduction of drug-
susceptible normal flora by antibiotic treatment may increase
vulnerability to acquisition of new strains. This effect will
increase the patient’s probability of being colonized with a
resistant organism if, during or shortly after treatment, he or
she is exposed to others with resistant organisms. This mecha-
nism is direct in the sense that it increases the treated patient’s
risk of colonization with resistant organisms but is also associ-
ated with indirect effects because of the requirement for trans-
mission. An index host given antibiotics is placed at greater
risk for colonization with resistant organisms (direct effect),
but this risk is amplified by his or her exposure to other
patients harboring resistant organisms, which is in turn
enhanced by their use of antibiotics (indirect effect). 
A fourth mechanism by which antimicrobial use increases
antimicrobial resistance is by increasing the density of resis-
tant organisms within a patient who already harbors such
organisms at a lower density (Figure, D; Table). Enhanced
shedding of these organisms, resulting in an increased risk to
other patients (an indirect effect), has been documented (i.e.,
in the case of anti-anaerobic agents that increase shedding of
vancomycin-resistant Enterococci (VRE) (24). An increased
risk of resistant infection to the treated patient (a direct effect)
Table. Mechanisms by which antimicrobial treatment has direct and indirect effects on resistance
Mechanism (effect of treatment)
Relationship between selection for 
resistance and treatment success
Relationship between no./dose of 
antibiotics and selection Examples Figure
Emergence of resistance 
during treatment (Da, Ib) 
↓d ↓ TB, HIV, Pseudomonas 
aeruginosa, Enterobacter spp.
1a
Reduced transmission of 
susceptible strains (I)
↑e ↑ May occur for nearly 
every infection 
1b
Increased susceptibility to 
colonization (D, I)
?c ? Commensals of skin, intestinal 
and respiratory tracts
1c
Increased density of colonization 
in individuals already colonized 
with resistant organisms, by 
inhibiting competitors (D,I)
? ↑- ? VREf and anti-anaerobic 
treatments
1d
aD=direct.
bI=indirect.
c?=relationship uncertain.
d↓inverse relationship.
e↑positive relationship.
fVRE=vancomycin-resistant Enterococci.PERSPECTIVES
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may occur if a higher density of resistant organisms places the
patient at higher risk of infection with his or her own flora.
Unlike the other three ways by which antimicrobial use pro-
motes resistance, this mechanism is mediated through antimi-
crobial treatment of patients already colonized with the
resistant organism. 
There are a number of other cases in which direct and indi-
rect effects of antibiotic treatment are combined.  Due to the
diversity of genetic mechanisms of resistance, the risk of
emergence of resistance during treatment represents a contin-
uum, with TB at one end and VRE (or MRSA) at the other.
Fluoroquinolone resistance in S. pneumoniae mediated by the
accumulation of mutations in the DNA gyrase and topo-
isomerase IV genes (25), or resistance to third-generation
cephalosporins in Enterobacteriaceae mediated by mutations
in TEM and SHV beta-lactamases located on plasmids (26),
lie between these two extremes. In these cases, multiple muta-
tions are required to turn a fully susceptible strain into a clini-
cally resistant one. For a patient colonized or infected with a
fully susceptible strain, emergence of resistance during treat-
ment may be highly unlikely because of the requirement for
selecting multiple mutations. However, in such cases, there
may be selection in consecutive hosts for small increases in
levels of resistance to a particular compound, resulting eventu-
ally in the emergence of clinical resistance (27). Patients may
be colonized with a mixed flora of resistant and susceptible
organisms, and eradication of the drug-susceptible flora may
permit outgrowth of the resistant subpopulation (28). This
mechanism has some formal similarity to what occurs in TB,
except that for a colonizing bacterium such as the pneumococ-
cus or the enteric colonizers, outgrowth of resistant organisms
in the site of colonization need not be associated with treat-
ment failure. In these cases, the treated patient is at increased
risk of carrying resistant organisms (direct effect), but an indi-
rect effect on the population occurs because the treated patient
no longer carries susceptible organisms and is, therefore,
unable to transmit them. 
Treatment with one antimicrobial drug can select for resis-
tance to a number of other, unrelated agents, by several means.
If individual organisms are resistant to multiple drugs, then use
of any one of these may promote resistance to others (29).
Additionally, by altering the balance of different components
of the indigenous microbial flora, treatment with one agent
may increase the load of a pathogen resistant to another agent,
simply by killing off competing flora of different species; this
has been observed, for example, with anti-anaerobic treat-
ments that increase the load of VRE (24). These complexities
increase the number of relationships that need to be studied in
assessing the effects of antimicrobial use on resistance and
also the number of potential confounders in any study.
Implications for Evaluating Treatment Strategies
Variation in mechanisms of resistance has implications for
the choice of antimicrobial therapy and the evaluation of strat-
egies to minimize resistance. Adopting the individual and
population-level perspective informs therapeutic decision-
making, clinical study design, and public policy.
In TB, preventing the emergence of resistance in a treated
host is a sound policy for averting the emergence of resistance
at the population level as well (although once resistant strains
have emerged, special measures are required to contain them
[30]). With respect to antimicrobial resistance, what is good
for the patient is good for the population. 
In contrast, for other types of resistance, antimicrobial
treatment may exert individual-level effects that are substan-
tially different in magnitude or even opposite in direction to
that of population-level effects. Treatment with a beta-lactam
may produce only a small, short-lived increase in the treated
patient’s odds of carrying or being infected by a resistant pneu-
mococcus (7). In some cases, treatment may actually eradicate
carriage of a resistant organism, thereby reducing the individ-
ual’s risk of resistant carriage. Small or unobservable effects
on individual risk have been observed in other cases as well,
such as vancomycin use for VRE (8, 31) and the use of various
antibiotics for infections with resitant gram-negative rods (32).
In these cases, preventing resistance in the treated patient may
not be the central goal of a prudent antibiotic use policy;
instead, treatment should seek to minimize the advantage it
provides to resistant organisms in the community or the hospi-
tal as a whole, subject to the constraint of providing effective
treatment for the patient. 
The considerations of the distinctive biologic and epidemi-
ologic mechanisms of antibiotic resistance in different patho-
gens lead to several broad suggestions for future studies. First,
the optimal study design to estimate individual-level effects of
antibiotics on colonizing organisms such as VRE and beta-lac-
tam resistant S. pneumoniae is to measure acquisition and loss
rates in an observational cohort or experimental study where
subjects are serially cultured before, during, and after antibi-
otic therapy (23, 33). Time-to-event statistical models (e.g.,
Cox proportional hazards regression) are appropriate analytic
methods for these kinds of studies (23, 31, 34). This design
allows investigators to distinguish between the effects of anti-
microbials on the risk for acquisition (colonization) and their
effects on the risk for clinical infection once an patient has
been colonized with a resistant organism. 
As a consequence of the mechanisms we have described,
the magnitude of an antibiotic’s effect on a patient’s risk of
resistant colonization or infection may be dependent on his or
her exposure to potential transmission of resistant organisms
(13). Stated differently, the frequency of contact with others
carrying the resistant organisms is likely an important effect-
modifier of antibiotic effects for pathogens that do not follow
the simple model of emergence of resistance exhibited by
organisms such as M. tuberculosis. Individual-level antibiotic
effects mediated by alterations in colonization resistance or
killing of susceptible bacteria may be greater in settings of
high exposure to resistant organisms, for example, during out-
breaks (7). Controlling for transmission risk or measuring
effects conditional on a specified level of transmission risk isEmerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 351
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advised, when possible. Standard analytic approaches make
the assumption that outcomes in different subject are
independent, but this assumption is violated in the case of
infectious diseases. Use of one of these strategies to model
exposure to transmission will help to account for this non-
independence of outcomes in different persons in the same
study (13, 35-37).
One practical result of quantifying direct, individual-level
antibiotic effects is to provide information on the short-term
risk of infection with a resistant organism to a person about to
initiate antibiotic treatment. This hazard needs to be taken into
account when weighing the risks and benefits of use of antimi-
crobial agents in individual patients. However, analogous to
the evaluation of vaccine programs, combined direct and indi-
rect antibiotic effects carry increased importance from the
public health and policy management perspective (38, 39).
The measurement of population-level effects of antimicrobials
also has educational value in demonstrating to clinicians and
patients the extent to which individual antibiotic use choices
have negative consequences for the population as a whole.
Such a conflict between individual benefit and the popula-
tion’s harm is an example of what economists term an “exter-
nality” or what environmentalists have called the “Tragedy of
the Commons” (40). 
To estimate overall antibiotic effects from data requires
group-level studies. Observational group-level studies may
lack sufficient data to avoid confounding and other causes of
ecologic bias (41). For this reason, studies that estimate the
effects of individual- and group-level antimicrobial use are
generally preferable to ones that contain group-level data
alone. Depending on the context, the appropriate group(s) may
include the family, the community, the hospital, or the hospital
unit or department (42-44). Further research is necessary to
evaluate hierarchical regression methods and compare results
obtained from different levels of analysis (44).
For the most accurate measurement of overall antibiotic
effect on resistance in communities, a cluster-randomized
intervention trial is appropriate (45). In cluster-randomized tri-
als, the unit of randomization is a group such as a community
or a hospital, and multiple units (sometimes as few as six, but
often more) are assigned to each of two (or more) treatment
arms. We are not aware of published studies using this design
to evaluate antibiotic resistance, although we know of two in
progress (R. Platt, pers. comm.) (12). However, this design has
been used in other areas of infectious disease epidemiology for
which group level effects are important (such as vaccination
programs), and it is considered the standard design for investi-
gations of the effects of insecticide-impregnated bednets in
preventing malaria (45-47). In the context of antimicrobial
resistance, cluster-randomized trials have two key advantages.
First, unlike studies that gather individual-level data alone,
they provide the opportunity to observe the indirect effects of
treatment on resistance. Second, they provide a clean way to
avoid the statistical problems of nonindependence between
patients in a study that may reduce the power or increase the
false-positive rate of observational studies. In cluster-random-
ized studies of antimicrobial resistance, both the incidence rate
of infection with resistant organisms in the population and the
ratio of resistant to susceptible (or proportion of total organ-
isms that are resistant) would be appropriate study endpoints. 
Role of Mathematical Models
Transmission-dynamic modeling can also play an impor-
tant role in bridging the gap between individual- and group-
level effects (20, 21, 48-50). These models take information
about individual-level effects as parameters and make predic-
tions about the response of the population to changes in such
parameters as transmission risk or antibiotic usage. Although
models cannot substitute for empirical intervention studies,
they can be particularly valuable in at least four ways: 1) gen-
erating hypotheses about the relationship between antibiotic
use and resistance that can be used in designing and prioritiz-
ing empirical studies; 2) defining the conditions under which a
particular intervention is likely to work, thereby suggesting
how empirical results can (and cannot) be extrapolated to other
settings; 3) providing explanations for phenomena that have
been observed but whose causes were uncertain; and 4) identi-
fying biological mechanisms that, while important, remain
poorly understood.
An example of models for generating hypotheses comes
from the question of antimicrobial rotation or “cycling.”
Cycling of antimicrobial classes in hospitals has been sug-
gested and is currently being evaluated for its ability to curtail
resistance in major nosocomial pathogens (5, 51-54). One
mathematical model of this process has suggested that using a
mixture of different drug classes simultaneously (e.g., if two
drug classes are available for empiric therapy of certain infec-
tions, treat half of the patients with one drug class and half
with the other) will reduce resistance more effectively than
cycling under a broad range of conditions (19). This suggests
that such mixed regimens would be good candidates for com-
parison with cycling in controlled trials.
As a second example, levels of resistance in hospital-
acquired pathogens may change rapidly within a matter of
weeks or months after changes in antimicrobial use. By con-
trast, studies of reductions in antimicrobial use in communities
have shown slow and equivocal effects on resistance in com-
munity-acquired pathogens (55). Mathematical models sug-
gest that, in communities, the key factor driving the change in
resistance levels may be the “fitness cost” of resistance, i.e.,
resistance will decline after a reduction in antimicrobial use if
resistant organisms in untreated patients are at a disadvantage
for transmission or persistence (20, 50, 56-57). This cost may
be small in many bacteria, accounting for the slow response
(55, 58). In contrast, a model indicates that, in hospitals,
changes in resistance may be driven primarily by the admis-
sion of new patients who often bring with them drug-suscepti-
ble flora, and this may rapidly “dilute” levels of resistance in
the absence of continuing selection by antibiotics (59). If cor-
rect, this explanation suggests that the success of antimicrobialPERSPECTIVES
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control measures should be evaluated differently for hospitals
and for communities. 
The use of mathematical models, and more generally the
attempt to predict the relative merits of different interventions,
will depend on an improved understanding of the mechanisms
of antibiotic selection in particular organisms. For example,
two recently published models for the nosocomial spread of
resistant pathogens made contrasting assumptions about
whether antimicrobial treatment increased an patient’s suscep-
tibility to colonization only during treatment (60) or for a
period following treatment (59), and about the importance of
colonization with drug-susceptible strains in protecting against
acquisition of resistant ones. As a result of these differences in
assumptions, predictions differed in important ways: one
model suggested that reduction of antibiotic use would be a
comparatively poor intervention when endemic transmission is
high and that resistant organisms could persist endemically
even in the absence of input from admitted patients or antibi-
otic selection (60). The other model predicted rapid declines in
the level of resistance when use is reduced, and a more com-
plicated relationship between the effectiveness of interven-
tions and the level of transmission within the hospital (59).
Testable predictions will permit the evaluation of different
models for particular settings and provide a basis for refining
the assumptions of these models. 
Conclusion 
The relationship between antibiotic usage and antibiotic
resistance for many types of pathogens is largely mediated by
indirect effects or population-level selection. When resistant
and susceptible organisms compete to colonize or infect hosts,
and use of an antibiotic has a greater impact on the transmis-
sion of susceptible bacteria than resistant ones, then increasing
use of the antibiotic will result in an increase in frequency of
organisms resistant to that drug in the population, even if the
risk for treated patients is modest. Antimicrobial use and
patient-to-patient transmission are not independent pathways
for promoting of antimicrobial resistance, rather they are inex-
tricably linked. 
Study designs to assess the effect of antimicrobial use on
resistance should reflect these diverse pathways of direct and
indirect effects. Estimates of direct effects of antimicrobial use
on treated patients will be most informative if clinical cultures
are combined with measurements of colonization. Use of time-
to-event (e.g., Cox proportional hazards) models provides a
natural way of controlling for the patient’s length of stay when
assessing the effect of treatment on acquisition of resistant
organisms. Analyses that control for a person’s exposure to
other patients carrying resistant organisms will help to capture
the effect modification because of varying transmission pres-
sures during a study. Inclusion of data on antimicrobial use by
the group to which others are exposed (siblings, fellow
patients on a hospital unit, total use in a community) and to
individual-level data will provide one method of estimating
both direct and indirect effects of antibiotic use. Nonindepen-
dence of individual outcomes makes the interpretation of inter-
vention studies problematic unless measures are taken to
account for this nonindependence; cluster-randomized studies,
used in other areas of infectious disease epidemiology, are an
excellent solution to this problem. We have commented else-
where on other aspects of study design for antimicrobial resis-
tance, notably the importance of control group selection
(7, 61-62).
Understanding in detail, for each pathogen, the mecha-
nisms by which antimicrobial use selects for antimicrobial
resistance in treated patients and in the population is of more
than academic importance. For practitioners, these mecha-
nisms matter for making well-informed decisions about the
design of treatment protocols, the choice of antibiotics and
doses for particular indications. For policymakers, these issues
have direct bearing on the design of campaigns to encourage
more rational antibiotic use and on the priorities in regulating
the use of antimicrobial agents for human and animal use
(63-64). 
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